이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Delcath Systems 관리

관리 기준 확인 1/4

Delcath Systems' CEO는 Gerard Michel, Oct2020 에 임명되었습니다 의 임기는 3.67 년입니다. 총 연간 보상은 $ 2.52M, 21.3% 로 구성됩니다. 21.3% 급여 및 78.7% 보너스(회사 주식 및 옵션 포함). 는 $ 2.31M 가치에 해당하는 회사 주식의 1.09% 직접 소유합니다. 2.31M. 경영진과 이사회의 평균 재임 기간은 각각 1.7 년과 4.1 년입니다.

주요 정보

Gerard Michel

최고 경영자

US$2.5m

총 보상

CEO 급여 비율	21.3%
CEO 임기	3.8yrs
CEO 소유권	1.1%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	4.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Gerard Michel 의 보수는 Delcath Systems 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$3m	US$538k	-US$48m
Sep 30 2023	n/a	n/a	-US$45m
Jun 30 2023	n/a	n/a	-US$34m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$1m	US$521k	-US$37m
Sep 30 2022	n/a	n/a	-US$33m
Jun 30 2022	n/a	n/a	-US$32m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	US$2m	US$475k	-US$26m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$25m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$6m	US$113k	-US$24m

보상 대 시장: Gerard 의 총 보상 ($USD 2.52M )은 US 시장( $USD 1.62M ).

보상과 수익: 회사가 수익성이 없는 동안 Gerard 의 보상이 증가했습니다.

CEO

Gerard Michel (61 yo)

3.8yrs

테뉴어

US$2,520,314

보상

Mr. Gerard J. Michel, MS, MBA, serves as Chief Executive Officer and Director at Delcath Systems Inc since October 1, 2020. He had been Chief Financial Officer and Vice President of Corporate Development a...

리더십 팀

이름	위치	테뉴어	보상	소유권
Gerard Michel	CEO & Director	3.8yrs	US$2.52m	1.09% $ 2.4m
Sandra Pennell	Senior VP of Finance and Principal Financial & Accounting Officer	1.1yrs	데이터 없음	0.22% $ 482.9k
Martha Rook	Chief Operating Officer	less than a year	데이터 없음	데이터 없음
David Hoffman	General Counsel	2.5yrs	데이터 없음	0.27% $ 587.9k
Johnny John	Senior Vice President of Clinical Operations & Medical Affairs	3.5yrs	US$737.50k	0% $ 0
Vojislav Vukovic	Chief Medical Officer	1.1yrs	데이터 없음	0.46% $ 1.0m

1.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: DCTH 의 관리팀은 경험 (평균 재직 기간 1.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gerard Michel	CEO & Director	3.8yrs	US$2.52m	1.09% $ 2.4m
Elizabeth Czerepak	Independent Director	4.4yrs	US$188.51k	0% $ 0
Steven Salamon	Independent Director	4.2yrs	US$183.96k	0.30% $ 650.2k
John Sylvester	Independent Chairman	5yrs	US$204.88k	0.038% $ 83.5k
Gilad Aharon	Independent Director	4.2yrs	US$172.96k	0.11% $ 244.3k
Bridget Martell	Director	less than a year	데이터 없음	데이터 없음

4.2yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: DCTH 의 이사회는 경험(평균 재직 기간 4.1 년)으로 간주됩니다.

Delcath Systems 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Delcath Systems, Inc. Appoints Bridget Martell to Board of Directors

Delcath Systems, Inc., Annual General Meeting, May 23, 2024

Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer

Delcath Systems, Inc. Announces Executive Changes

CEO & Director recently bought US$100k worth of stock

Chief Medical Officer recently bought US$149k worth of stock

Recent updates

Delcath Systems, Inc. Appoints Bridget Martell to Board of Directors

New major risk - Financial position

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Consensus revenue estimates increase by 11%

Price target increased by 8.1% to US$20.80

Delcath Systems, Inc. to Report Q1, 2024 Results on May 14, 2024

Delcath Systems, Inc Announces Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT

Delcath Systems, Inc., Annual General Meeting, May 23, 2024

Forecast breakeven date pushed back to 2026

Delcath Systems, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer

Delcath Systems, Inc. Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

Delcath Systems, Inc. Announces Executive Changes

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024

Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing Hepzato Kit™

Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?

No longer forecast to breakeven

CEO & Director recently bought US$100k worth of stock

Chief Medical Officer recently bought US$149k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 34%

Insufficient new directors

Delcath Systems (NASDAQ:DCTH) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates fall by 18%

Independent Chairman recently bought US$51k worth of stock

CEO & Director exercised options to buy US$171k worth of stock.

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

Price target increased by 11% to US$18.20

Consensus EPS estimates upgraded to US$1.92 loss

New major risk - Shareholder dilution

No longer forecast to breakeven

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Delcath Systems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

Delcath Systems, Inc. Appoints Sandra Pennell as Senior Vice President of Finance

Delcath Systems, Inc. Provides Preliminary Earnings Guidance for the First Quarter Ended March 31, 2023

Consensus revenue estimates decrease by 46%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Delcath Systems, Inc. Announces Board Changes

Delcath Systems, Inc. Announces New Drug Application Resubmission for HEPZATO Kit

Delcath Systems Announces Updated Results from Chopin Phase 1B Trial Published in Cardiovascular and Interventional Radiology

Forecast to breakeven in 2025

Independent Director recently bought US$55k worth of stock

Delcath Systems, Inc. announced that it has received $6.201779 million in funding

Delcath Systems, Inc. Announces Results of Single Center Study on Delcath's CHEMOSAT Hepatic Delivery System in the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$18.20

Delcath Systems, Inc. Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Results of A Multicenter Study on Delcath's Chemosat Hepatic Delivery System Published in Cardiovascular and Interventional Radiology

Delcath Systems Q2 2022 Earnings Preview

CEO & Director recently bought US$250k worth of stock

Delcath Systems, Inc. announced that it has received $4.999998 million in funding

Delcath Systems, Inc. announced that it expects to receive $5.000038 million in funding

Delcath Systems to raise $5M in stock and warrants offering

Delcath Systems: Revisiting A $5 Lottery Ticket

Price target decreased to US$21.20

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Price target decreased to US$22.00

Delcath Systems, Inc., Annual General Meeting, May 04, 2022

Consensus forecasts updated

Is Delcath Systems (NASDAQ:DCTH) Weighed On By Its Debt Load?

Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT

Delcath Systems, Inc. Appoints Anthony Dias as its New Vice President of Finance

Delcath Systems, Inc. Announces Result of Single Center Study on Delcath’s CHEMOSAT Hepatic Delivery System Published in Melanoma Research

CEO & Director recently bought US$200k worth of stock

Price target increased to US$23.50